Genprex, Inc. (GNPX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol GNPX
- Company Genprex, Inc.
- Price $1.1
- Changes Percentage -14.4
- Change -0.185
- Day Low $1.1
- Day High $1.37
- Year High $14.4
- Year Low $0.28
- Market Cap $9,358,875
- Price Avg 50 EMA (D) $1.05
- Price Avg 200 EMA (D) $2.16
- Exchange NASDAQ
- Volume 961,335
- Average Volume 9,569,690
- Open $1.37
- Previous Close $1.29
- EPS -10.69
- PE -0.10
- Earnings Announcement 2025-03-28 12:00:00
- Shares Outstanding $8,508,068
Company brief: GENPREX, INC. (GNPX )
- Healthcare
- Biotechnology
- Dr. Mark S. Berger M.D.
- https://www.genprex.com
- US
- N/A
- 03-29-2018
- US3724462037
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
GNPX Corporation News
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
prnewswire.com -- License includes Genprex's Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung Cancer AUSTIN, Texas , Nov. 20, 2024 /PRNewswire/ -- Genprex, In...
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
prnewswire.com -- REQORSA Modulates In Vivo Immune Responses Against Cancers AUSTIN, Texas , Nov. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy compan...
Genprex to Participate in 2024 BIO Europe Conference
prnewswire.com -- AUSTIN, Texas , Oct. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patie...
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
prnewswire.com -- Preclinical Data Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics AUSTIN, Texas , Oct. 28, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company")...
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
prnewswire.com -- Research to Study TUSC2 Combined with ALK-Inhibitors Collaboration with Non-Profit Patient-Focused Research Group Expands Potential Lung Cancer Patient Population for Reqorsa® Gene Therapy AUSTIN, Te...